Upsher-Smith La Patent-Cliff Exposure & CMS Drug Spending Portfolio
Upsher-Smith La (US): 13 reconciled FDA prescription therapies, $222.4M 2024 CMS Part D & Medicaid spend, and $14,929 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 13 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $222.4M |
| 2024 Medicare Part D Spend | $142.7M |
| 2024 Medicaid Spend | $79.7M |
| California HCAI SB 17 Filings | Specialty launch notice ($14,929 intro WAC) |